EyePoint, Inc. (EYPT)
NASDAQ · Manufacturing · Laboratory analytical instruments
$3.62−$0.0300 (−0.82%) on the dayAs of the close; data may be delayed.
EYPT price, last 12 months
Key stats
- Previous close
- $3.65
- Open
- $3.65
- Day range
- $3.56 – $3.71
- 52-week range
- $3.42 – $19.11
- Volume
- 2.3M
- Avg volume (20 days)
- 3.7M
- Market cap
- $312.1M
Performance
1W−6.0%
1M−27.5%
3M−73.5%
6M−72.3%
YTD−80.2%
1Y−74.3%
vs S&P 500, 1Y−91.1 pts
Technicals and fundamentals
About EyePoint, Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
- Sector
- Manufacturing
- Industry
- Laboratory analytical instruments
- Listed on
- NASDAQ
- Market cap
- $312.1M